ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - rivaroxaban - טבליות מצופות פילם - rivaroxaban 15 mg - rivaroxaban

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - rivaroxaban - טבליות מצופות פילם - rivaroxaban 20 mg - rivaroxaban

ישראל - עברית - Ministry of Health

taro pharmaceutical industries ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 2.5 mg - rivaroxaban

ישראל - עברית - Ministry of Health

abbvie biopharmaceuticals ltd, israel - foscarbidopa; foslevodopa - תמיסה לאינפוזיה - foslevodopa 240 mg / 1 ml; foscarbidopa 12 mg / 1 ml

ישראל - עברית - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 40 mg - pantoprazole - pantoprazole - short term treatment of acute duodenal ulcer. acute gastric ulcer. moderate and severe reflux esophagitis. eradication of helicobacter pylori in combination with clarithromycin and amoxycillin or clarithromycin and metronidazole or amoxycillin and metronidazole in cases of duodenal ulcer and gastric ulcer with the objective of reducing of duodenal and gastric ulcers caused by this microorganism. zollinger ellison syndrome.

ישראל - עברית - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 20 mg - pantoprazole - pantoprazole - treatment of reflux oesophagitis and associated symptoms (e.g. hearburn acid regurgitation pain on swallowing) . for long-term management and prevention of relapse in reflux oesophagitis. prevention of gastroduodenal ulcers induced by non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaids treatment.

ישראל - עברית - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

ישראל - עברית - Ministry of Health

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 900 - 1300 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

ישראל - עברית - Ministry of Health

csl behring ltd., israel - human fibrinogen - אבקה להמסה להזרקה\אינפוזיה - human fibrinogen 1800 - 2600 mg / 1 vials - fibrinogen, human - fibrinogen, human - haemocomplettan p 1g/2g, fibrinogen concentrate (human) is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.haemocomplettan p 1g/2g is not indicated for dysfibrinogenemia.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.